Published by Wanda Rich
Posted on April 23, 2025
As per industry analysis on vancomycin market by Fact.MR, a market research and competitive intelligence provider, the global market is predicted to expand at a CAGR of 5.8% over the forecast period and reach US$ 465.1 million by 2027.
The human body is home to a wide range of microorganisms. Staphylococcus aureus, a gram-positive bacterium that is most typically found on the human skin and nasal passages, is one of them. The market for vancomycin is developing due to increasing prevalence of this infection. Increasing government and non-government awareness campaigns are also expected to contribute to market growth.
The global vancomycin market is being driven by increased incidence of diseases caused by vancomycin-resistant Staphylococcus aureus (VRSA), and poor sanitation, which, in turn, increases the risk of hospital-acquired infections.
VRSA infections can be treated with a range of commercially available drugs, but maintaining basic sanitary conditions, including wound care, hand washing before and after direct contact with patients, and the use of disposable gloves, is the most effective strategy for preventing the spread of VRSA.
Vancomycin is used as a first-line and second-line treatment, depending on the diseases for which it is prescribed. The global market for vancomycin is predicted to rise over the next years owing to increasing demand for antibiotics. The market is reliant on the number of processed prescriptions for cases, which is increasing at an unprecedented rate.
For More Insights into the Market, Request a Sample of this Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=7293
Key Takeaways from Market Study:
“Healthcare beneficiaries play a key part in the movement, influencing corporations to develop pharmaceuticals for comprehensive treatment. Rising initiatives by government organizations for the development of novel drugs and treatments are supporting vancomycin market growth,”says a Fact.MR analyst
Leading Players Driving Innovation in the Vancomycin Market:
Alvogen; MGB Biopharma Limited; Oragenics; Aphios Corporation; Microbiotix
Winning Strategy:
To increase their market position across geographies, vancomycin suppliers are investing in the research and development of new medicines. Key players are also working hard to secure regulatory approvals for their products.
For instance,
Vancomycin Market News:
In February 2022, Magnolia Medical Technologies, Inc., manufacturer of Steripath®, the sole FDA 510(k)-compliant device platform for minimizing blood culture contamination for sepsis testing1, announced US$ 46 million of growth equity funding co-led by RTW Investments, LP ("RTW"), and Sectoral Asset Management
Get Customization on this Report for Specific Research Solutions: https://www.factmr.com/connectus/sample?flag=S&rep_id=7293
More Valuable Insightson Offer:
Fact.MR, in its new offering, presents an unbiased analysis of the global vancomycin market, presenting historical demand data (2017-2020) and forecast statistics for the period of 2021-2027.
The study divulges essential insights on the market on the basis of type (daptomycin, linezolid, quinupristin, ampicillin, chloramphenicol, and others) and application (sepsis, lung infection, skin soft tissue infection, colitis & intestinal inflammation, and other infections), across five major regions (North America, Europe, Asia Pacific, Latin America, and MEA).
Check out More Related Studies Published by Fact.MR Research:
The global Clostridium difficile infection treatment market size is set to reach US$ 1.24 billion by the end of 2024 and climb to US$ 2.28 billion by the end of 2034, expanding at a CAGR of 6.3% between 2024 and 2034.
The global antibacterial drugs market, the market is projected to expand at a CAGR of 2.6% through 2031, and reach a valuation of over US$ 62 Bn by 2031, surpassing US$ 51 Bn by 2025. As of the next half-a-decade, the market is anticipated to register a CAGR of 1.5%.
The global medical education market is projected to reach a value of US$ 35.11 billion in 2024. Worldwide revenue from the sales of medical education solutions is forecasted to increase at a CAGR of 5.1% and reach US$ 57.95 billion by the end of 2034.
The global heart failure monitoring systems market was valued at US$ 13,379.4 million in 2023 and has been forecasted to expand at a noteworthy CAGR of 5.7% to end up at US$ 24,612.2 million by 2034.
The global upper airway stimulation market is valued at US$ 572.4 million in 2023 and is forecasted to expand at a noteworthy CAGR of 12.3% to end up at US$ 2,050.6 million by 2034.
